Join our live process intensification webinars
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptates natus esse, deserunt necessitatibus numquam amet rerum dicta in, iste sequi cupiditate distinctio voluptate et veritatis.
— quote source
As the drive towards targeted cost-effective biopharmaceuticals continues, improving flexibility and agility while getting more output from existing facilities through process intensification has become more important. Join us for a series of process intensification webinars covering upstream, downstream, and buffer management to help you find the best strategies for tomorrow.
Register now - Wednesday, 27 Jan 2021 10:00 EST | 15:00 GMT
Buffer preparation is still a highly manual activity in the biopharmaceutical industry that often requires a lot of resources due to the large number and overall volume of buffers and process liquids used in a typical bioprocess workflow.
In biomanufacturing, seven out of the ten downstream equipment types with the longest occupancy duration are buffer related. Holding tanks reserved for buffers also require significant floor space in large-scale production facilities that could be used for other core operations.
As a result, buffer preparation can create bottlenecks in the manufacturing process.
Most companies are still relying on the traditional ways of preparing buffers, but there are more modern, alternative buffer preparation methods that can bring significant savings and efficiency improvements while ensuring high quality.
It is critical that every process is evaluated for the optimal buffer management strategy as there is no one solution that fits all processes.
For example, outsourced premade buffers can be a simple and fast way to gain new capacity, especially in process development and in “downsized” single-use facilities, providing speed-to-market and flexibility.
With inline conditioning and inline dilution, where buffers are prepared in-line from buffer concentrates or stock solutions, buffer preparation can be directly integrated with the chromatography or filtration step. This eliminates the need for intermediate storage in buffer bags or holding tanks, bringing significant reductions in floor space and tank volumes with increased automation.
In this webinar you will learn:
• Advantages, sweet spots, and drawbacks with the different buffer preparation approaches through real-life, data-driven examples
• Important considerations for choosing the right buffer management strategy
• How to assure consistent buffer quality with inline dilution and inline conditioning, or when outsourcing buffers
• What are the technical capabilities focusing on quality that are built into these approaches?
• Buffer management trends and biopharmaceutical companies’ long term-strategies for the future
Jenny holds a Master of Science in Molecular biotechnology engineering from Uppsala University, Sweden. She started her career in the Life Science and Medical Technology areas with different positions within marketing, sales and application support. In 2015, she joined Cytiva as Global Product Marketing Manager for the downstream hardware portfolio and was the marketing lead for the launch of the successful ÄKTA pilot 600. In 2018, she moved to the product management organization. Jenny is inspired by people and is always eager to learn and use her creative mind.
As a Global Product Manager with the ready-made Process Liquids and Buffers portfolio, Alexander has been exposed to many customers that all have the common challenge of managing buffers in a rapidly growing environment while simultaneously trying to maximize current efficiencies.
Alexander’s background is well rounded as he completed his doctorate in Cell and Tissue engineering at the University of Illinois at Chicago in the Bioengineering department. Thereafter, he joined Baxter Healthcare as an R&D Global Project Leader and worked in three separate locations while leading global programs in device development and clinical program management, moving to Austria in the process.
This presentation will describe strategies to intensify upstream operations. We will discuss the latest trends across the industry in relation to process intensification and give specific examples of how both N-1 and N bioreactor operations can be intensified using the latest technologies. Furthermore, we will discuss the importance of cell culture media optimization prior to implementation of any new process.
In this webinar you will learn:
• The importance of cell culture media optimization in perfusion operations
• How intensified N-1 operations can increase facility utilization and productivity
• The pros and cons of various perfusion operations in the production bioreactor
Andreas Castan is Strategic Technology Partnerships Leader for Cytiva. In this role, Andreas provides leadership and support to the Bioprocess business. His main area of expertise is in upstream processing. Prior to joining Cytiva, Andreas was Director of Upstream Development at Swedish Orphan Biovitrum, working with development of expression systems, process development of microbial and mammalian cell-based processes, and scale-up to cGMP manufacturing scales. During the last 20 years, Andreas has held several positions within biopharmaceutical development, including project and line management as well as manufacturing.
There is no misrepresentation in the potential of connected and continuous manufacturing. So why isn’t everyone adopting these benefit-packed processes? This presentation will share Cytiva's strategy for building confidence in technology and process knowledge. It will also address the regulatory expectations and business case examples for connected & continuous processes in biomanufacturing’s future.
In this webinar you will learn:
• A pragmatic approach to start-to-finish connected bioprocessing
• Process design strategies and its dependence on desired outcome
• Implementation and execution strategies
As a Connected Biomanufacturing Program leader, Avril brings strong experience from large-scale bioprocessing and a profound understanding of process intensification. Avril joined the GE Healthcare’s Life Sciences business, now Cytiva, in 2015 as a Bioprocess Hardware Specialist. She loves lending her large-scale bioprocess expertise to help colleagues select and implement process solutions that optimize efficiency and productivity. Her contributions have led to several successful tech transfers globally, including Amgen Singapore’s Next Generation Manufacturing facility. Prior to her time in Amgen’s process development organization, she worked in manufacturing and process engineering at Diosynth. She currently serves as an ISPE Rocky Mountain Chapter board director and a Facility of the Year Award (FOYA) committee chair and has been an ISPE member since joining the student chapter at North Carolina State University where she received her degree in Chemical Engineering. She is currently pursuing an Executive MBA at the University of Colorado.
Process intensification and implementation of perfusion technologies can help provide greater efficiency to upstream operations. This presentation will describe how a fully automated, single-use perfusion system can mitigate many of the challenges currently faced when implementing perfusion processes at production scale.
In this webinar you will learn:
• Different ways to intensify cell culture operations
• How Xcellerex APS takes risky manual operations out of perfusion applications
• That a fully integrated perfusion operation can be implemented using standard systems
With a Master’s in biotechnology, Radhika has been in the Consumer Products and Biopharma industry for the last 17 years. She has had a diverse career with roles in research and development, business development, and product management. Her focus over the last 3 years, as New Product Introductions Leader within Cytiva, has been in the Continuous Bioprocessing segment. Here she has led the devolvement of Xcellerex APS from product concept through to commercialization.
6 May 10:00AM EDT | 16:00 CEST Register
To address the growing demand for plasmid DNA, Cobra Biologics have embarked on a collaborative project with GE healthcare to develop a second generation PlasmidSelect resin based on Cytiva’s Capto bioprocessing resin. This presentation with look at the needs within the plasmid DNA market and how this collaboration has sought to address this market opportunity
Tony has over 35 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programs for the development of novel therapeutic products including protein, recombinant virus, bacteriophage and plasmid DNA products. His current role is based in the commercial group and support external collaboration and outreach activities. Additionally Tony is currently a member of the BIA Science and Innovation Advisory Committee (SIAC) and of industrial advisory boards for Aston and Loughborough Universities
8 April 10:00AM EDT | 16:00 CEST Register
There is no misrepresentation in the potential of connected and continuous manufacturing. So why isn’t everyone adopting these benefit-packed processes? This presentation will share GE’s strategy for the building confidence in technology & process knowledge. It will also address the regulatory expectations and business case examples for connected & continuous processes in biomanufacturing’s future.
Avril Vermunt, Connected Biomanufacturing Program Manager
As a Connected Biomanufacturing Program leader, Avril brings strong experience from large scale bioprocessing and a profound understanding of process intensification. Avril joined the GE Healthcare’s Life Sciences business in 2015 as a Bioprocess Hardware Specialist. She loves lending her large-scale bioprocess expertise to help colleagues select and implement process solutions that optimize efficiency and productivity. Her contributions have led to several successful tech transfers globally, including Amgen Singapore’s Next Generation Manufacturing facility. Prior to her time in Amgen’s process development organization, she worked in manufacturing and process engineering at Diosynth. She currently serves as an ISPE Rocky Mountain Chapter board director and a Facility of the Year Award (FOYA) committee chair, and has been an ISPE member since joining the student chapter at North Carolina State University where she received her degree in Chemical Engineering. She is currently pursuing an Executive MBA at the University of Colorado.
8 April 10:00AM EDT | 16:00 CEST Register
There is no misrepresentation in the potential of connected and continuous manufacturing. So why isn’t everyone adopting these benefit-packed processes? This presentation will share GE’s strategy for the building confidence in technology & process knowledge. It will also address the regulatory expectations and business case examples for connected & continuous processes in biomanufacturing’s future.
Avril Vermunt, Connected Biomanufacturing Program Manager
As a Connected Biomanufacturing Program leader, Avril brings strong experience from large scale bioprocessing and a profound understanding of process intensification. Avril joined the GE Healthcare’s Life Sciences business in 2015 as a Bioprocess Hardware Specialist. She loves lending her large-scale bioprocess expertise to help colleagues select and implement process solutions that optimize efficiency and productivity. Her contributions have led to several successful tech transfers globally, including Amgen Singapore’s Next Generation Manufacturing facility. Prior to her time in Amgen’s process development organization, she worked in manufacturing and process engineering at Diosynth. She currently serves as an ISPE Rocky Mountain Chapter board director and a Facility of the Year Award (FOYA) committee chair, and has been an ISPE member since joining the student chapter at North Carolina State University where she received her degree in Chemical Engineering. She is currently pursuing an Executive MBA at the University of Colorado.
8 April 10:00AM EDT | 16:00 CEST Register
There is no misrepresentation in the potential of connected and continuous manufacturing. So why isn’t everyone adopting these benefit-packed processes? This presentation will share GE’s strategy for the building confidence in technology & process knowledge. It will also address the regulatory expectations and business case examples for connected & continuous processes in biomanufacturing’s future.
Avril Vermunt, Connected Biomanufacturing Program Manager
As a Connected Biomanufacturing Program leader, Avril brings strong experience from large scale bioprocessing and a profound understanding of process intensification. Avril joined the GE Healthcare’s Life Sciences business in 2015 as a Bioprocess Hardware Specialist. She loves lending her large-scale bioprocess expertise to help colleagues select and implement process solutions that optimize efficiency and productivity. Her contributions have led to several successful tech transfers globally, including Amgen Singapore’s Next Generation Manufacturing facility. Prior to her time in Amgen’s process development organization, she worked in manufacturing and process engineering at Diosynth. She currently serves as an ISPE Rocky Mountain Chapter board director and a Facility of the Year Award (FOYA) committee chair, and has been an ISPE member since joining the student chapter at North Carolina State University where she received her degree in Chemical Engineering. She is currently pursuing an Executive MBA at the University of Colorado.
8 April 10:00AM EDT | 16:00 CEST Register
There is no misrepresentation in the potential of connected and continuous manufacturing. So why isn’t everyone adopting these benefit-packed processes? This presentation will share GE’s strategy for the building confidence in technology & process knowledge. It will also address the regulatory expectations and business case examples for connected & continuous processes in biomanufacturing’s future.
Avril Vermunt, Connected Biomanufacturing Program Manager
As a Connected Biomanufacturing Program leader, Avril brings strong experience from large scale bioprocessing and a profound understanding of process intensification. Avril joined the GE Healthcare’s Life Sciences business in 2015 as a Bioprocess Hardware Specialist. She loves lending her large-scale bioprocess expertise to help colleagues select and implement process solutions that optimize efficiency and productivity. Her contributions have led to several successful tech transfers globally, including Amgen Singapore’s Next Generation Manufacturing facility. Prior to her time in Amgen’s process development organization, she worked in manufacturing and process engineering at Diosynth. She currently serves as an ISPE Rocky Mountain Chapter board director and a Facility of the Year Award (FOYA) committee chair, and has been an ISPE member since joining the student chapter at North Carolina State University where she received her degree in Chemical Engineering. She is currently pursuing an Executive MBA at the University of Colorado.